An evolutionary paradigm for carcinogenesis?

Journal of Epidemiology and Community Health

Volumn 57, Issue 2, 2003, Pages 89-95

  Vineis, P ^a,b   Matullo, G ^a,b   Manuguerra, M ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b ISI FOUNDATION   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; COLORECTAL CARCINOMA; DIETARY INTAKE; DNA ADDUCT; DNA FINGERPRINTING; FRUIT; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MATHEMATICAL MODEL; MOLECULAR CLONING; MOLECULAR EVOLUTION; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENTIATION; SURVIVAL RATE; VEGETABLE;

CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DNA ADDUCTS; GENES, APC; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; SELECTION (GENETICS);

EID: 0037310299     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.57.2.89     Document Type: Review

References (46)

1. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001;357:709-12.
2. Strohman RC. The coming Kuhnian revolution in biology. Nat Biotechnol 1997;15:194-200.
3. Vineis P, Malats N, Porta M, et al. Human cancer, carcinogenic exposures and mutational spectra. Mutation Res 1999;436:185-94.
4. Haddow A. Sir Ernest Laurence Kennaway FRS, 1881-1958: chemical causation of cancer then and today. Perspect Biol Med 1974;17:543-88.
5. Lawley PD, Brookes P. Molecular mechanism of the cytotoxic action of difunctional alkylating agents and of resistance to this action. Nature 1965;206:480-3.
6. Hussain SO, Hollstein M, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 2000;919:79-85.
7. Denissenko MF, Koudriakova TB, Smith L, et al. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene 1998;17:3007-14.
8. Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
9. Rodin SN, Rodin AS. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 2000;97:12244-9.
10. Hainaut P, Pfeifer GP. Patterns of p53 G ta T transversions in lung cancers reflect th eprimary mutageni signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
11. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996;93:14025-9.
12. Iversen OH. The skin tumorigenic and carcinogenic effects of different doses, number of dose fractions and concentrations of 7,12-dimethylbenz(a)anthracene in acetone applied in hairless mouse epidermis. Possible implications for human carcinogenesis. Carcinogenesis 1991;12:493-502.
13. International Agency for Research on Cancer. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol 38. Tobacco smoking. Lyon: IARC, 1986.
14. Eldredge N. Reinventing Darwin. The great debate at the high table of evolutionary theory. New York: Wiley, 1995.
15. Leigh EG. The evolution of mutation rates. Genetics 1973;73:1-18.
16. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genomic instability. Bioessays 1994;16:833-9.
17. Toddei F, Radman M, Maynard-Smith J, et al. Role of mutator alleles in adaptive evolution. Nature 1997;387:700-2.
18. LeClerc JE, Li B, Payne WL, et al. High mutation frequencies among Escherichia coli and Salmnonella pathogens. Science 1996;274:1208-11.
19. Haraguchi Y, Sasaki A. Host-parasite arms race in mutation modifications: indefinite escalation despite a heavy load? J Theor Biol 1996;183:121-37.
20. Tomlinson I, Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 1999;5:11-12.
21. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumours: a mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000;97:3352-7.
22. Rosse WF. New insights into paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology 2001;8:61-7.
23. Vineis P, Perera F. DNA adducts as markers of exposure to carcinogens and risk of cancer. Int J Cancer 2000;88:325-8.
24. Peluso M, Airoldi L, Magagnotti C, et al. White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer. Carcinogenesis 2000;21:183-7.
25. Davidson LA, Lupton JR, Jiang YK, et al. Carcinogen and dietary lipid regulate ras expression and localization in rat colon without affecting farnesylation kinetics. Carcinogenesis 1999;20:785-91.
26. Duthie SJ, Narayanan S, Blum S, et al. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer 2000;37:245-51.
27. Choi SW, Kim YI, Weitzel JN, et al. Folate depletion impairs DNA excision repair in the colon of the rat. Gut 1998;43:93-9.
28. Wiencke JK, Thurston SW, Kelsey KT, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst 1999;91:614-19.
29. Vulimiri SV, Wu X, Baer-Dubowska W, et al. Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo-2′ deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. Mol Carcinog 2000;27:330.
30. Bardelli A, Cahill DP, Lederer G, et al. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci USA 2001;98:5770-5.
31. Porta M, Malats N, Alguacil J, et al. Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. J Epidemiol Community Health 2000;54:656-9.
32. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001;84:417-22.
33. Airoldi I, Orsi F, Magagnotti C, et al. Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 2002;23:861-6.
34. st century. Persp Biol Med 1998;42:44-75.
35. McCully KS. The significance of wheat in the Dakota territory, human evolution, civilization, and degenerative diseases. Persp Biol Med 2001;44:52-61.
36. Steen HB. The origin of oncogenic mutations: where is the primary damage? Carcinogenesis 2000;21:1773-6.
37. International Agency for Research on Cancer. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol. 23. Some metals and metallic compounds. Lyon: IARC, 1986.
38. Smith AH, Goycolea M, Haque R, et al. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 1998;147:660-9.
39. Ko YC. A critical review of epidemiologic studies on black-foot disease. Journal of the University of Occupational and Environmental Health 1986;8:339-53.
40. Brown CC, Chu KC. Implications of the multistage theory of carcinogenesis applied to occupational arsenic exposure. J Natl Ccancer Inst 1983;70:455-63.
41. Germolec DR, Spalding J, Yu HS, et al. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 1998;153:1775-85.
42. Wu W, Graves LM, Jaspers I, et al. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am J Physiol 1999;277:L924-31.
43. Van Tongeren JH, Kunst A, Majoor CL, et al. Folic-acid deficiency in chronic arsenic poisoning. Lancet 1965;i:784-6.
44. Basu A, Mahata J, Gupta S, et al. Genetic toxicology of a paradoxical human carcinogen, arsenic: a review. Mut Res 2001;488:171-94.
45. Gatenby RA. Application of competition theory to tumour growth: implications for tumour biology and treatment. Eur J Cancer 1996;32A:722-6.
46. Ormerod P. The death of economics. New York: Wiley, 1997.